MedTrace Logo

Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate

NCT05083299 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1003

Last updated 2024-07-03

No results posted yet for this study

Summary

The study will evaluate the effect of Anpl-one SR Tablet on the improvement of symptoms in daily care environments using PAQ.

Conditions

  • Chronic Occlusive Arterial Disease

Interventions

DRUG

Sarpogrelate

Anpl-one SR

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • BuKyung Kim · Kosin University Hospital

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-28
Primary Completion
2022-01-20
Completion
2022-01-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05083299 on ClinicalTrials.gov